The effectiveness of an improved combination therapy for experimental XXXX keratitis.

@entity32 @entity3256 @entity2890 @entity267 @entity794 @entity95 @entity134 @entity281 @entity619 @entity735 @entity9845
INTRODUCTION: antibiotic and @entity134 combination therapies, such as @entity2890 with @entity619 , are often used in ophthalmology to treat or prevent @entity281 and @entity32 . The purpose of this study was to use a model of @entity794 keratitis to quantify and compare the effectiveness of a standard @entity2890 and @entity619 combined therapy, with each drug individually, and with a new formulation of the two drugs in a xanthan gum vehicle. METHODS: @entity95 corneas were intrastromally injected with a @entity3256 -sensitive @entity794 (MSSA) or a @entity3256 -resistant @entity794 ( @entity794 . @entity95 eyes were treated every hour from 10 to 15 hours postinfection (PI) with 0.1% @entity619 , 0.3% @entity2890 , 0.3% @entity2890 with 0.1% @entity619 , or 0.3% @entity2890 with 0.05% @entity619 in a xanthan gum vehicle (ST). @entity9845 ( @entity9845 ) were performed on infected eyes and pathology scored at 15 hours PI. At 16 hours PI, colony forming units (CFUs) per @entity267 were quantified. RESULTS: the CFUs in eyes treated with @entity619 alone were similar to untreated control eyes for MSSA or @entity794 infections. All other treatment groups had significantly less CFUs per @entity735 . The eyes treated with the ST formulation had significantly fewer CFUs per @entity267 than all other treatment groups when infected with MSSA or @entity794 . The @entity9845 scores of MSSA or @entity794 infected eyes treated with @entity2890 alone were similar to untreated control eyes. All other treatment groups had significantly lower @entity9845 scores than untreated controls eyes, but were not significantly different from each other. CONCLUSION: the results of this study demonstrated that the @entity2890 and @entity619 combination therapy with a xanthan gum vehicle has an improved bactericidal effectiveness compared to the commercially available formulation, and maintains a similar anti-inflammatory effect while containing half the amount of @entity134 .
